Alvotech (ALVO) Reports Prelim Q2 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Alvotech (ALVO) Reports Prelim Q2 Results

Alvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

July 1, 2024 5:10 AM EDT

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced certain preliminary, unaudited key financial information for the second quarter and six months ended June 30, 2024, as follows:

Strong preliminary revenue growth with total revenues for the second quarter between $196 - $201 million. Preliminary total revenues for the first six months are $233 - $238 million, an approximately 10-fold increase compared to total revenues for the same period in 2023. Preliminary product revenues, from global sales of Alvotechs biosimilars to Humira® (adalimumab) and Stelara® (ustekinumab), for the... More